Literature DB >> 2105839

Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.

P H Quax1, R T van Leeuwen, H W Verspaget, J H Verheijen.   

Abstract

In 22 human tumor cell lines the regulation of production of plasminogen activators urokinase (u-PA) and tissue-type (t-PA) and their inhibitors PAI-1 and PAI-2 was studied. These four components may determine the net plasminogen activator activity, which is often associated with tumor development and metastatic processes. The amount of specific mRNA and protein produced by the cells was measured for all four components. The frequent finding of t-PA (alone or in combination with u-PA) suggests that t-PA can also be a tumor-associated plasminogen activator. In 11 of the 22 cells PAI-1 mRNA and in 6 of the 22 cells PAI-2 mRNA was found, pointing to a possible role of plasminogen activator inhibitors in the tumor-related plasminogen activator activity. This study demonstrates that there are at least two important regulatory steps in the regulation of production of plasminogen activators and their inhibitors: (a) the regulation at the mRNA level, since a high protein amount is always correlated with a high mRNA amount found in the tumor cells; (b) there must be a significant regulatory step at the (post)translational level as can be concluded from differences in mRNA usage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105839

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

2.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

3.  Differential expression of SKALP/Elafin in human epidermal tumors.

Authors:  H A Alkemade; H O Molhuizen; I M van Vlijmen-Willems; U J van Haelst; J Schalkwijk
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

4.  Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1.

Authors:  M Osmak; I Vrhovec; J Skrk
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

5.  Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase.

Authors:  J H Verheijen; N M Nieuwenbroek; B Beekman; R Hanemaaijer; H W Verspaget; H K Ronday; A H Bakker
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

6.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

7.  Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors.

Authors:  J S Rao; A Rayford; R A Morantz; B W Festoff; R Sawaya
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

Review 8.  Adhesion molecules and their role in cancer metastasis.

Authors:  R M Lafrenie; M R Buchanan; F W Orr
Journal:  Cell Biophys       Date:  1993 Aug-Dec

9.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

Authors:  C F Sier; H W Verspaget; G Griffioen; S Ganesh; H J Vloedgraven; C B Lamers
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

10.  Identification of one- and two-chain forms of trypsinogen 1 produced by a human gastric adenocarcinoma cell line.

Authors:  N Koshikawa; H Yasumitsu; Y Nagashima; M Umeda; K Miyazaki
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.